Pay in 4 interest-free payments of $6.66 Learn more
Ships within 48 hours · Estimated delivery Aug 15 - Aug 20
Dihexa peptide is currently not widely available as it is still under investigation and pending approval through clinical trials
GLP-1 treatments are generally prescribed to individuals in the obese category or those in the overweight category with additional health risks
In Trial 7, cholecystitis was reported in 1.1% of patients treated with RYBELSUS 14 mg and in 0.7% of placebo-treated patients [see Adverse Reactions (6.1)]
Under the Medicare GLP-1 Bridge, eligible beneficiaries can get Medicare coverage of GLP-1s for obesity for a $50 monthly copayment, which will not count towards the Part D deductible or out-of-pocket spending cap and Part D Low-Income Subsidy cost-sharing assistance will not apply
